Immutep Share Price and Company Fundamentals

0.005 (1.053%)
52 week
0.18 - 0.725

Last traded: Today at 6:10 AM

Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ‘eftilagimod alpha' or ‘efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Key Metrics

PE ratio


PB ratio


Dividend yield



Market cap


Enterprise value


Company profile

Primary activitiesbiotechnology and medical research
Industry / SectorBiotechnology / Healthcare
Mailing address95 Pitt Street Level 12 Sydney NSW 2000 Australia
Phone / Fax61 2 8315 7003 / 61 2 8569 1880


Immutep does not pay dividends.

Company Executives

As of Jul 2021, following are the company executives and directors listed on Immutep.

NameTitleAgeTotal Pay
Mr. Marc VoigtCEO, CFO, Chief Bus. Officer & Exec. Director47456.42k
Ms. Deanne MillerCOO, Gen. Counsel & Joint Company Sec.43280.12k
Dr. Frederic TriebelChief Scientific Officer & Chief Medical Officer65279.12k
Ms. Indira NaiduJoint Company Sec.
Mr. Christian MuellerDirector of Clinical Devel. & Regulatory Affairs
Mr. Shengfei FangFin. Director & Assistant Company Sec.

Profitability and management effectiveness

Profit margin


Operating margin


Return on assets


Return on equity


Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Immutep is 311.39M and its enterprise value is 266.26M. The enterprise value to revenue ratio of IMM is 41.91.

The IMM's stocks Beta value is 1.45 making it 45% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Immutep (IMM)

Immutep (ASX:IMM) Frequently Asked Questions

1. What is Immutep's Stock Symbol?

Immutep trades on ASX under the ticker symbol "IMM".

2. What is Immutep's stock price today?

One share of IMM stock can currently be purchased for approximately $0.48.

3. How can I contact Immutep?

Immutep's mailing address is 95 Pitt Street Level 12 Sydney NSW 2000 Australia. The company can be reached via phone at 61 2 8315 7003.

4. What is Immutep's official website?

The official website of Immutep is

5. Which share registry manages Immutep's stock?

Immutep's stock is managed by BOARDROOM PTY LIMITED.